Hemispherx Biopharma, Inc. announced that Adam Pascale is retiring from the position of Chief Financial Officer after nearly a quarter century with the company. Pascale joined Hemispherx in 1995 as an accounting manager, rising to the position of Chief Accounting Officer before being named CFO in 2016. Pascale has been an integral part of Hemispherx’s leadership team since being named CFO, helping to execute CEO Thomas K. Equels’ long-term business plan to test the company’s lead product Ampligen in the treatment of cancer. Most recently, Pascale helped guide the company’s successful reverse-stock split, which took effect June 10, 2019. Although stepping down as CFO, Pascale will still be working with Hemispherx as a consultant to assist with the company’s quarterly and year-end financial reports.